U.S. markets closed

  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     

  • Dow 30

    33,963.84
    -106.58 (-0.31%)
     

  • Nasdaq

    13,211.81
    -12.18 (-0.09%)
     

  • Russell 2000

    1,776.50
    -5.32 (-0.30%)
     

  • Crude Oil

    90.33
    +0.70 (+0.78%)
     

  • Gold

    1,944.90
    +5.30 (+0.27%)
     

  • Silver

    23.82
    +0.13 (+0.56%)
     

  • EUR/USD

    1.0647
    -0.0015 (-0.14%)
     

  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     

  • GBP/USD

    1.2240
    -0.0054 (-0.44%)
     

  • USD/JPY

    148.3600
    +0.7970 (+0.54%)
     

  • Bitcoin USD

    26,578.60
    -29.89 (-0.11%)
     

  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     

  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     

  • Nikkei 225

    32,402.41
    -168.62 (-0.52%)
     

Midday movers: Abercrombie & Fitch, Petco Health, Palo Alto Networks and more

Investing.com
·1 min read

Investing.com -- Stocks are falling on Wednesday as negotiations on the debt ceiling dragged on with the deadline swiftly approaching. Here are the market movers for May 24.

Abercrombie&Fitch Company (NYSE:ANF) shares jumped 27% as the specialty retailer reported a surprise profit for the first quarter and a gain in net sales, led by its namesake brand amid a reinvention. Shares of fellow retailer Kohl’s Corp (NYSE:KSS), which operates department stores, also jumped 7.7% after a surprise profit. Petco Health and Wellness Company Inc (NASDAQ:WOOF) shares fell 15% after the pet supply retailer provided weak revenue guidance for the current quarter. It beat expectations for the first quarter. Palo Alto Networks Inc (NASDAQ:PANW) shares rose 7.4% after the cybersecurity firm raised its guidance for profit, sales and billings for the fiscal year. Its third-quarter adjusted profit beat expectations. Intuit Inc (NASDAQ:INTU) shares fell 6.9% after the maker of financial software such as TurboTax reported third-quarter revenue below forecasts. While it raised its outlook for the full fiscal year, it gave a fourth-quarter profit estimate that fell short of expectations.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares slid 11% after the biotech said the Food and Drug Administration was pushing back a decision date on its muscular dystrophy gene therapy by about a month.

Related Articles

Biden administration urges Supreme Court not to hear Apple-Caltech patent case

JPMorgan can sue former executive Staley over Epstein ties -US judge